Search

Displaying results 4141 - 4150 of 5898 in total
  1. Drug

    Androstenediol

    go.drugbank.com/drugs/DB01524
    ExperimentalIllicit

    to a 3-keto group (3-hydroxysteroid dehydrogenases). … Androstenediol, derived from dehydroepiandrosterone by the reduction of the 17-keto group (17-hydroxysteroid dehydrogenases), is converted to testosterone by the oxidation of the 3-beta hydroxyl group

  2. Drug

    Budigalimab

    go.drugbank.com/drugs/DB16668
    Investigational

    With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis). … Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination

  3. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively. … [L45469] In February 2023, Kinnate Biopharma received Fast Track designation from the FDA for KIN-3248 to treat unresectable, locally advanced or metastatic cholangiocarcinoma (CCA).[L45474]

  4. Drug

    MK-0354

    go.drugbank.com/drugs/DB05939
    Investigational

    It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.

  5. Drug

    Rose bengal

    go.drugbank.com/drugs/DB11182
    ApprovedInvestigational

    Its disodium salt in ophthalmic solutions has been used as a diagnostic agent in suspected damage to conjunctival and corneal cells.

  6. Drug

    Talactoferrin alfa

    go.drugbank.com/drugs/DB05426
    Investigational

    It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.

  7. Drug

    LErafAON

    go.drugbank.com/drugs/DB04973
    Investigational

    NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation

  8. Drug

    N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide

    go.drugbank.com/drugs/DB06945
    Experimental

    This substance is known to target a disintegrin and metalloproteinase with thrombospondin motifs 5. … This compound belongs to the diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.

  9. Drug

    Lomedeucitinib

    go.drugbank.com/drugs/DB21649
    Investigational

    Lomedeucitinib is under investigation in clinical trial NCT05730725 (A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis).

  10. Drug

    Bioymifi

    go.drugbank.com/drugs/DB17493
    Experimental

    Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.